Condition: Achondroplasia · Sponsor: Ascendis Pharma A/S
The purpose of this clinical trial is to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of navepegritide 100 μg/kg compared to placebo (inactive drug) in adolescents aged 12 to 18 years with Achondroplasia. What will be measured is Annualized Growth Velocity after a 52-week treatment period.
This description comes directly from the study's public registry record.
Ascendis Registry Inquiries · +4561242484 · asnd_registryinquiries@ascendispharma.com
Always discuss trial participation with your own doctor first.
| Ascendis Investigational Site | Montreal, Canada | Recruiting |
| Ascendis Investigational Site | Copenhagen, Denmark | Recruiting |
| Ascendis Investigational Site | Paris, France | Recruiting |
| Ascendis Investigational Site | Dublin, Ireland | Recruiting |
| Ascendis Investigational Site | Norwich, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06732895